Last reviewed · How we verify
RSV A Memphis 37b
At a glance
| Generic name | RSV A Memphis 37b |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model (PHASE2)
- Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) (PHASE2)
- An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults (PHASE2)
- Phase 2a Study of MVA-BN-RSV Vaccination and RSV Challenge in Healthy Adults (PHASE2)
- Phase 2a Respiratory Syncytial Virus (RSV) Human Challenge Study of Clesrovimab (MK-1654) in Healthy Participants (MK-1654-005) (PHASE2)
- Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine (PHASE2)
- A Phase 2a Study to Evaluate EDP-938 in the Virus Challenge Model (PHASE2)
- Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |